U.S. health insurer Humana Inc. and two private equity firms agreed to buy home healthcare and long-term care operator Kindred Healthcare Inc. for about $810 million, the latest expansion by an American health insurer into patient care.
Novo Nordisk came closer to winning European approval for the company’s diabetes drug Ozempic, the Danish drugmaker’s largest growth prospect, when a European Medicines Agency experts’ panel issued a positive recommendation.
Merck KGaA is reviving plans to bring an oral multiple sclerosis (MS) treatment to the U.S. market, hoping for blockbuster sales despite regulatory concerns about side effects having frustrated the German company’s ambitions almost seven years ago.
Revance Therapeutics Inc. will wait to seek partnerships with bigger drugmakers until the company is closer to regulatory approval for its Botox rival treatment, Chief Executive Dan Browne told Reuters in an interview.
Smart Hospitals to Invest over $11 billion in Cloud Computing and Data Analytics, Says Frost & Sullivan
By 2025, 10 percent of hospitals across the globe will become or will have started implementations to become smart hospitals.
Sage Therapeutics Inc.’s drug to treat patients with moderate to severe depression met the main goal in a mid-stage study.
Adding Roche’s immunotherapy Tecentriq to older drugs doubled the percentage of lung cancer patients who survived a year without their disease advancing, an outcome some experts labelled unprecedented.
The largest U.S. health insurer UnitedHealth Group Inc will buy DaVita Inc’s primary and urgent care services for $4.9 billion in its second acquisition this year.
The U.S. FDA approved Novo Nordisk A/S’ diabetes drug Ozempic, setting the stage for a heated battle with Eli Lilly & Co.’s Trulicity.
Indivior’s experimental drug to help fight America’s growing opioid addiction crisis was approved by the U.S. Food and Drug Administration, boosting the company’s sales prospects as competitors threaten revenues from an older product.